Spinal Muscular Atrophy (SMA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Spinal Muscular Atrophy Drugs Development Market Overview

Spinal muscular atrophy (SMA) pipeline market research report provides comprehensive information on the therapeutics under development for Spinal Muscular Atrophy (SMA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Spinal Muscular Atrophy (SMA) and features dormant and discontinued projects.

Key Targets in the Spinal Muscular Atrophy (SMA) Pipeline Market

The key targets in the spinal muscular atrophy pipeline market are Survival Motor Neuron Protein, Growth/Differentiation Factor 8, Androgen Receptor, Huntingtin, Potassium Channel Voltage Gated, Chloride Channel Protein 1, Free Radical, and Glycogen Synthase Kinase 3. Survival Motor Neuron Protein has the highest pipeline products.

Spinal Muscular Atrophy (SMA) Pipeline Market, by Targets

Spinal Muscular Atrophy (SMA) Pipeline Market, by Targets

For more target insights, download a free report sample

Key MoA in the Spinal Muscular Atrophy (SMA) Pipeline Market

The key MoA in the spinal muscular atrophy pipeline market are Survival Motor Neuron Protein Activator, Growth/Differentiation Factor 8 Inhibitor, Androgen Receptor Inhibitor, Potassium Channel Voltage Gated Blocker, Androgen Receptor Antagonist, Chloride Channel Protein 1 Blocker, and Free Radical Scavenger. Survival Motor Neuron Protein Activator has the highest number of pipeline products.

Spinal Muscular Atrophy (SMA) Pipeline Market, by MoA

Spinal Muscular Atrophy (SMA) Pipeline Market, by MoA

For more MoA insights, download a free report sample

Key RoA in the Spinal Muscular Atrophy (SMA) Pipeline Market

The key RoA in the spinal muscular atrophy pipeline market are oral, intrathecal, intravenous, subcutaneous, intracerebral, intraocular, and parenteral. Oral has the highest share in the spinal muscular atrophy pipeline market.

Spinal Muscular Atrophy (SMA) Pipeline Market, by RoA

Spinal Muscular Atrophy (SMA) Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Types in the Spinal Muscular Atrophy (SMA) Pipeline Market

The key molecule types in the spinal muscular atrophy pipeline market are small molecule, gene therapy, antisense oligonucleotide, cell therapy, monoclonal antibody, recombinant protein, antibody, biologic, fusion protein, oligonucleotide, and protein. Small molecule has the highest pipeline products.

Spinal Muscular Atrophy (SMA) Pipeline Market, by Molecule Types

Spinal Muscular Atrophy (SMA) Pipeline Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Companies in the Spinal Muscular Atrophy (SMA) Pipeline Market

The key companies in the spinal muscular atrophy pipeline market are Biogen Inc, Apteeus SAS, BioMarin Pharmaceutical Inc, F. Hoffmann-La Roche Ltd, Myocea Inc, Novartis Gene Therapies, Oncternal Therapeutics, Alcyone Therapeutics Inc, and AlphaCognition Inc. Biogen Inc has the highest pipeline products.

Spinal Muscular Atrophy (SMA) Pipeline Market, by Companies

Spinal Muscular Atrophy (SMA) Pipeline Market, by Companies

To know more about companies, download a free report sample

Market report overview

Key targets Survival Motor Neuron Protein, Growth/Differentiation Factor 8, Androgen Receptor, Huntingtin, Potassium Channel Voltage Gated, Chloride Channel Protein 1, Free Radical, and Glycogen Synthase Kinase 3
Key MoA Survival Motor Neuron Protein Activator, Growth/Differentiation Factor 8 Inhibitor, Androgen Receptor Inhibitor, Potassium Channel Voltage Gated Blocker, Androgen Receptor Antagonist, Chloride Channel Protein 1 Blocker, and Free Radical Scavenger
Key RoA Oral, Intrathecal, Intravenous, Subcutaneous, Intracerebral, Intraocular, and Parenteral
Key molecule types Small Molecule, Gene Therapy, Antisense Oligonucleotide, Cell Therapy, Monoclonal Antibody, Recombinant Protein, Antibody, Biologic, Fusion Protein, Oligonucleotide, and Protein
Key companies Biogen Inc, Apteeus SAS, BioMarin Pharmaceutical Inc, F. Hoffmann-La Roche Ltd, Myocea Inc, Novartis Gene Therapies, Oncternal Therapeutics, Alcyone Therapeutics Inc, and AlphaCognition Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Muscular Atrophy (SMA) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Spinal Muscular Atrophy (SMA) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Spinal Muscular Atrophy (SMA) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Spinal Muscular Atrophy (SMA) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Muscular Atrophy (SMA) (Central Nervous System)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Spinal Muscular Atrophy (SMA) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Alcyone Therapeutics Inc
AlphaCognition Inc
Amniotics AB
Anima Biotech Inc
Annji Pharmaceutical Co Ltd
Apteeus SAS
ARMGO Pharma Inc
Beijing GeneCradle Technology Co Ltd
Biocad
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
Bioleaders Corp
BioMarin Pharmaceutical Inc
Biophytis SA
Cell Tech Pharmed Co
Chugai Pharmaceutical Co Ltd
Enzerna Biosciences LLC
Exegenesis Bio Inc
F. Hoffmann-La Roche Ltd
Genentech USA Inc
GNT Pharma Co Ltd
Huida (Shanghai) Biotechnology Co Ltd
Imago Pharmaceuticals Inc
Myocea Inc
Neurotune AG
NMD Pharma AS
Novartis AG
Novartis Gene Therapies
Oncternal Therapeutics
Ono Pharmaceutical Co Ltd
PTC Therapeutics Inc
Ractigen Therapeutics Inc
Reborna Biosciences Inc
Sarepta Therapeutics Inc
Scholar Rock Inc
Shift Pharmaceuticals
Spotlight Innovation Inc
Suzhou GenAssist Therapeutics Co Ltd
Voyager Therapeutics Inc
Vybion Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Spinal Muscular Atrophy (SMA) – Overview

Spinal Muscular Atrophy (SMA) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Spinal Muscular Atrophy (SMA) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Spinal Muscular Atrophy (SMA) – Companies Involved in Therapeutics Development

Alcyone Therapeutics Inc

AlphaCognition Inc

Amniotics AB

Anima Biotech Inc

Annji Pharmaceutical Co Ltd

Apteeus SAS

ARMGO Pharma Inc

Beijing GeneCradle Technology Co Ltd

Biocad

Biogen Inc

Biohaven Pharmaceutical Holding Company Ltd

Bioleaders Corp

BioMarin Pharmaceutical Inc

Biophytis SA

Cell Tech Pharmed Co

Chugai Pharmaceutical Co Ltd

Enzerna Biosciences LLC

Exegenesis Bio Inc

F. Hoffmann-La Roche Ltd

Genentech USA Inc

GNT Pharma Co Ltd

Huida (Shanghai) Biotechnology Co Ltd

Imago Pharmaceuticals Inc

Myocea Inc

Neurotune AG

NMD Pharma AS

Novartis AG

Novartis Gene Therapies

Oncternal Therapeutics

Ono Pharmaceutical Co Ltd

PTC Therapeutics Inc

Ractigen Therapeutics Inc

Reborna Biosciences Inc

Sarepta Therapeutics Inc

Scholar Rock Inc

Shift Pharmaceuticals

Spotlight Innovation Inc

Suzhou GenAssist Therapeutics Co Ltd

Voyager Therapeutics Inc

Vybion Inc

Spinal Muscular Atrophy (SMA) – Drug Profiles

AAD-2004 – Drug Profile

Product Description

Mechanism Of Action

ACTX-401 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ALB-111 – Drug Profile

Product Description

Mechanism Of Action

ALPHA-0602 – Drug Profile

Product Description

Mechanism Of Action

ALZ-002 – Drug Profile

Product Description

Mechanism Of Action

History of Events

amifampridine phosphate – Drug Profile

Product Description

Mechanism Of Action

History of Events

ANB-4 – Drug Profile

Product Description

Mechanism Of Action

Antisense Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy – Drug Profile

Product Description

Mechanism Of Action

Antisense Oligonucleotides for Spinal Muscular Atrophy – Drug Profile

Product Description

Mechanism Of Action

apitegromab – Drug Profile

Product Description

Mechanism Of Action

History of Events

ARM-210 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BIIB-089 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BIIB-110 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BIIB-115 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BIO-101 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BLSM-22 – Drug Profile

Product Description

Mechanism Of Action

branaplam hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

CogniStem – Drug Profile

Product Description

Mechanism Of Action

Drugs for Neuromuscular Diseases and Spinal Muscular Atrophy (SMA) – Drug Profile

Product Description

Mechanism Of Action

History of Events

E-1V111 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ENZ-001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

GC-101 – Drug Profile

Product Description

Mechanism Of Action

GEN-8010 – Drug Profile

Product Description

Mechanism Of Action

Gene Therapies to Activate SMN1 for Spinal Muscular Atrophy – Drug Profile

Product Description

Mechanism Of Action

Gene Therapy for Spinal Muscular Atrophy – Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy – Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Activate SYT13 for Amyotrophic Lateral Sclerosis and Spinal Muscular Atrophy – Drug Profile

Product Description

Mechanism Of Action

GTP-201 – Drug Profile

Product Description

Mechanism Of Action

History of Events

GTx-505 – Drug Profile

Product Description

Mechanism Of Action

History of Events

HG-001 – Drug Profile

Product Description

Mechanism Of Action

INT-41 – Drug Profile

Product Description

Mechanism Of Action

History of Events

maresin-1 – Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibody to Inhibit Myostatin for Spinal Muscular Atrophy – Drug Profile

Product Description

Mechanism Of Action

History of Events

NMDP-02 – Drug Profile

Product Description

Mechanism Of Action

NT-1654 – Drug Profile

Product Description

Mechanism Of Action

onasemnogene abeparvovec – Drug Profile

Product Description

Mechanism Of Action

History of Events

ONCT-534 – Drug Profile

Product Description

Mechanism Of Action

History of Events

PMO-25 – Drug Profile

Product Description

Mechanism Of Action

History of Events

RAG-06 – Drug Profile

Product Description

Mechanism Of Action

Resagen – Drug Profile

Product Description

Mechanism Of Action

History of Events

RG-6237 – Drug Profile

Product Description

Mechanism Of Action

History of Events

risdiplam – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule for Spinal Muscular Atrophy – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit GSK-3 for Spinal Muscular Atrophy – Drug Profile

Product Description

Mechanism Of Action

Small Molecules 2 to Activate SMN2 for Spinal Muscular Atrophy – Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Central Nervous System Disorders – Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Kennedy’s Disease – Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Spinal Muscular Atrophy – Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Spinal Muscular Atrophy – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules for Spinal Muscular Atrophy – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Activate SMN2 for Spinal Muscular Atrophy – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Antagonize AR for Spinal and Bulbar Muscular Atrophy – Drug Profile

Product Description

Mechanism Of Action

History of Events

STL-182 – Drug Profile

Product Description

Mechanism Of Action

History of Events

talditercept alfa – Drug Profile

Product Description

Mechanism Of Action

History of Events

TEC-1 – Drug Profile

Product Description

Mechanism Of Action

TEE-375 – Drug Profile

Product Description

Mechanism Of Action

TEE-703 – Drug Profile

Product Description

Mechanism Of Action

timrepigene emparvovec – Drug Profile

Product Description

Mechanism Of Action

History of Events

Vartocell – Drug Profile

Product Description

Mechanism Of Action

Spinal Muscular Atrophy (SMA) – Dormant Projects

Spinal Muscular Atrophy (SMA) – Discontinued Products

Spinal Muscular Atrophy (SMA) – Product Development Milestones

Featured News & Press Releases

Mar 22, 2022: Scholar Rock presents data analysis of multiple efficacy endpoints from the apitegromab TOPAZ phase 2 trial at the American Academy of Neurology 2022 Annual Meeting

Mar 16, 2022: New data for Roche’s Evrysdi (risdiplam) demonstrate long-term efficacy and safety in a broad population of people with spinal muscular atrophy (SMA)

Mar 16, 2022: New data for Genentech’s Evrysdi (risdiplam) demonstrate long-term efficacy and safety in a broad population of people with Spinal Muscular Atrophy (SMA)

Mar 13, 2022: Scholar Rock to present data from TOPAZ Ambulatory Cohort Analysis at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 13, 2022: Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection

Mar 08, 2022: Roche to present new Evrysdi data at MDA 2022 and highlight expanding neuromuscular disease portfolio

Feb 03, 2022: Roche Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for EVRYSDI (risdiplam) for the treatment of adults and children with spinal muscular atrophy (SMA)

Jan 31, 2022: Cost-effectiveness analysis temporarily halted for Zolgensma to collect long-term data

Jan 25, 2022: Roche’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies under 2 months of age with spinal muscular atrophy (SMA)

Nov 30, 2021: Scholar Rock announces design of phase 3 SAPPHIRE clinical trial evaluating apitegromab in non-ambulatory patients with Type 2 and Type 3 spinal muscular atrophy (SMA)

Nov 19, 2021: NICE draft guidance recommends new treatment for spinal muscular atrophy as part of a managed access agreement

Oct 19, 2021: Novartis applauds Quebec, the first province to list Zolgensma for the treatment of pediatric patients with spinal muscular atrophy (SMA)

Oct 13, 2021: Novartis and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for Zolgensma for the treatment of pediatric patients with spinal muscular atrophy (SMA)

Oct 03, 2021: Scholar Rock to present Apitegromab TOPAZ phase 2 pharmacologic data at the 2021 World Congress of Neurology

Sep 30, 2021: Scholar Rock presents exploratory responder analysis on efficacy data from the apitegromab TOPAZ phase 2 trial at the Child Neurology Society Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Spinal Muscular Atrophy (SMA), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Alcyone Therapeutics Inc, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by AlphaCognition Inc, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Amniotics AB, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Anima Biotech Inc, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Annji Pharmaceutical Co Ltd, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Apteeus SAS, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by ARMGO Pharma Inc, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Beijing GeneCradle Technology Co Ltd, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Biocad, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Biogen Inc, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Bioleaders Corp, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by BioMarin Pharmaceutical Inc, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Biophytis SA, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Cell Tech Pharmed Co, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Chugai Pharmaceutical Co Ltd, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Enzerna Biosciences LLC, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Exegenesis Bio Inc, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by F. Hoffmann-La Roche Ltd, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Genentech USA Inc, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by GNT Pharma Co Ltd, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Huida (Shanghai) Biotechnology Co Ltd, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Imago Pharmaceuticals Inc, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Myocea Inc, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Neurotune AG, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by NMD Pharma AS, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Novartis AG, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Novartis Gene Therapies, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Oncternal Therapeutics, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Ono Pharmaceutical Co Ltd, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by PTC Therapeutics Inc, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Ractigen Therapeutics Inc, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Reborna Biosciences Inc, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Sarepta Therapeutics Inc, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Scholar Rock Inc, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Shift Pharmaceuticals, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Spotlight Innovation Inc, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Suzhou GenAssist Therapeutics Co Ltd, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Voyager Therapeutics Inc, 2022

Spinal Muscular Atrophy (SMA) – Pipeline by Vybion Inc, 2022

Spinal Muscular Atrophy (SMA) – Dormant Projects, 2022

Spinal Muscular Atrophy (SMA) – Dormant Projects, 2022 (Contd..1)

Spinal Muscular Atrophy (SMA) – Dormant Projects, 2022 (Contd..2)

Spinal Muscular Atrophy (SMA) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Spinal Muscular Atrophy (SMA), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Spinal Muscular Atrophy (SMA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Spinal Muscular Atrophy (SMA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Spinal Muscular Atrophy (SMA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.